USFDA, DCA discuss ways to boost pharma manufacturing and drug quality in Andhra Pradesh
The USFDA and Andhra Pradesh's Drug Control Administration held a workshop to discuss improving pharmaceutical manufacturing standards and regulatory collaboration. The event focused on ensuring drug quality through scientific approaches and rigorous inspection methodologies.
Why it matters
As a major global pharmaceutical hub, Andhra Pradesh's regulatory compliance is critical for maintaining the safety and reliability of medicine supply chains for the U.S. and international markets.
The officials of the Drug Control Administration (DCA) in Andhra Pradesh and U.S. Food and Drug Administration (USFDA) discussed ways to strengthen global regulatory collaboration and promote scientific pharmaceutical manufacturing at the Regulatory Workshop–2026 in the city on Friday.
The officials of USFDA, DCA, US Pharmacopeia (USP) and All India Drugs Control Officers’ Confederation (AIDCOC) participated in the day-long event that focused on the theme, ‘Ensuring Drug Quality: Scientific Approach in Regulations, Standards and Inspections’.
Drug inspectors, government analysts, regulators, representatives from various pharma industries, and technical experts from across the State artended the workshop.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in